Our research
The team leader Martin Jädersten is ̽ѡ lead for acute myeloid leukemia (AML) at the Karolinska University Hospital and a member of the steering committees for the Swedish and Nordic AML Groups. He has extensive experience in state-of-the art management of AML as well as translational and clinical trials. The focus of the group is to improve outcome in AML, both by optimizing prognostication and by translating laboratory data into innovative clinical trials.
The team is a part of the Sören Lehmann research group at the Center for Hematology and Regenerative Medicine (HERM) .
Our research spans from laboratory projects to investigator-initiated clinical trials primarily in AML, and to some extent in other myeloid disorders such as myelodysplastic syndromes (MDS) and histiocytosis. We collaborate with several groups at HERM as well as at ̽ѡ Solna, other sites in Sweden, and research groups abroad.
One research line concerns the resistance factor SAM domain and HD domain-containing protein 1 (SAMHD1), inactivating cytarabine which is the backbone of most standard chemotherapy regimens used in AML. Current projects explore the role of SAMHD1 in de novo AML, relapsed refractory AML, and in myelosarcoma.
Another focus is high-throughput drug screening and multi-omics, where primary cells from AML patients are assessed for a broad panel of chemotherapeutics and targeted drugs.
The group also investigates epidemiological aspects of AML, focusing on emerging therapies, home care of patients with AML, and changes over time with respect to prognosis and early mortality.
Finally, we run investigator-initiated trials in AML, both therapeutic studies with novel drug combinations and projects where patients are sampled for laboratory analyses, both functional studies and analysis of measurable residual disease.
Main collaborators
SAMHD1-related projects, including the clinical trials HEAT-AML and FLAsH-IV-AML: Nikolas Herold, Department of Women’s and Children’s health, KI
Drug screening and multiomics, including the LD-VenEx-AML trial: Tom Erkers, SciLifeLab KI
Myelosarcoma and functional studies. Hong Qian, HERM, KI
Karolinska AML Biobank, Sören Lehmann, HERM, KI